[New antiplatelet drugs].
Platelet-aggregation inhibitors are the cornerstone of the treatment and prevention of atherothrombotic events. Long limited to aspirin alone, new drugs have appeared in the past two decades. But only very recently have new targets been developed. The synergy of their mechanisms of action now makes it possible to obtain ever stronger inhibition of platelet aggregation.